BRAF and melanoma: The BRAF V600E mutation, at least in part, induces angiogenesis through HIF-1α/VEGF, and the treatment of SK-MEL-28 melanoma cells with the BRAF inhibitor PLX4720 reduces VEGF expression and secretion.